BVS (Bioventus) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


BVS Bioventus Inc BVS
69 GF Score
Price $9.73
GF Value $6.79
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Bioventus Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Bioventus's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BVS vs NPCE, TCMD, CERS: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Bioventus's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioventus Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Bioventus's Margin of Safety % (DCF Earnings Based) falls into.


BVS
69GF Score
Bioventus Inc BVS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioventus (BVS) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventus stock appears to be overvalued. The current stock price of $9.73 is trading 43.3% above its estimated GF Value™ of $6.79. GuruFocus considers Bioventus to be Significantly Overvalued.

Key valuation signals for BVS:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $6.79 vs. price of $9.73 (43.3% above fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventus Business Description

Address 4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
69GF Score

Get the complete analysis for BVS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.73
Price
$6.79
GF Value